United States · 
What does Agent Capital invest in?
Agent Capital invests most often at Series B and Series A (100% of the rounds on record), in sectors such as Rare Diseases, Oncology and Neurology.
Agent Capital highlights
- 01
1 cheques in the last 12 months
- 02
Mostly Series B and Series A: 100% of its rounds
What they do
Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- $250K – $15M as they say
- Stages
- Pre-seedSeedSeries ASeries BGrowth
- Sectors
- Rare DiseasesOncologyNeurology
- Based in
- Waltham, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first6 appearances
- 2026
1 round
- Oct
- 2025
1 round
- Jan
- 2024
2 rounds
- Nov
- Nov
- 2023
1 round
- Nov
- 2019
1 round
- Dec
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration2 named
GSGeeta Shastry VemuriManaging Member of the General Partner and Managing Partner of the Management CompanyiFiling they signed
PJPreston Joseph NoonMemberiForm ADV
We also hold 5 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$140Mgross assets of its fundsOct 2026
2+funds on filenumbered funds in its name
Exemptreporting adviserventure or small private funds
- Legal name
- Agent Capital, LLC
- SEC number
- CRD 288532
What they claim to have backed
From their own portfolio page (on their website)
7 of 11 we have independently watched raise
CerevanceCyrusbioHingebioPrimrosebioQ32bioStar-therapeuticsVergegenomicsAshibioCarbonbioNu-tekbiosciencesVittoriabio
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.